According to our latest study on “Non-Alcoholic Steatohepatitis (NASH) Market Forecast to 2028 – COVID-19 Impact and Global Analysis – Product, Application, and Sales Channel," the market is expected to grow from US$ 1,631.92 million in 2021 to US$ 24,266.81 million by 2028; it is estimated to grow at a CAGR of 47.1% from 2021 to 2028.
The report highlights the major factors driving the market, and prominent players and their developments in the market. The growth of the non-alcoholic steatohepatitis (NASH) market is mainly driven by the rising prevalence of NASH and increasing initiatives for the awareness of NASH. However, the lack of established guidelines for the diagnosis and withdrawal of drugs from the marketing authorization stage of clinical trials hamper the market growth.
NASH had the strongest association with COVID-19 of all comorbid metabolic conditions, including hypertension and obesity. Liver injury in the form of increased transaminases and hyperbilirubinemia among COVID-19 patients can be attributed to a couple of factors, including pre-existing liver disease. The comorbidity of nonalcoholic fatty liver disease (NAFLD) and NASH in these patients makes them prone to severe forms of liver injury. The presence of fibrosis rather than NASH/NAFLD is associated with worse clinical outcomes and higher mortality in COVID-19 patients.
The impact of COVID-19 on comorbid patient populations, including people with diabetes, obesity, fatty liver disease, and NASH, has triggered the need of providing optimal care to patients. Research revolving around combating NAFLD and NASH indicates that the anticipated relationship with obesity is stark. Therefore, a high incidence of NASH demands advanced diagnostics and treatments, which boosts research and development in the market. Thus, the COVID-19 crisis has fueled the non-alcoholic steatohepatitis (NASH) market growth.
The non-alcoholic steatohepatitis (NASH) market, by product, is segmented into vitamin E and pioglitazone, ocaliva, elafibranor, selonsertib & cenicriviroc, and others. In 2021, the others segment held the largest share of the market. The selonsertib & cenicriviroc segment is expected to register the fastest CAGR in the non-alcoholic steatohepatitis (NASH) market from 2021 to 2028. Further, the selonsertib & cenicriviroc segment is anticipated to register the highest CAGR of 73.3% in the market during the forecast period. Selonsertib is an oral inhibitor of apoptosis signal-regulating kinase 1 (ASK1), with potential anti-inflammatory, antineoplastic and anti-fibrotic activities. It is under investigation in clinical trial NCT03053050—Safety and Efficacy of Selonsertib in Adults with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis. Cenicriviroc (CVC) is a potent chemokine 2 and 5 receptor antagonist that is currently being developed for the treatment of liver fibrosis in individuals with NASH. Various research studies and clinical trials are being conducted worldwide for selonsertib and CVC, which are expected to drive the market during the forecast period.
Genfit SA; One Way Liver, S.L.; BioPredictive S.A.S.; Cadila Pharmaceuticals Ltd.; Prometheus Laboratories; Siemens Healthineers AG; Intercept Pharmaceuticals, Inc.; Novartis AG; Galmed Pharmaceuticals; and Laboratory Corporation of America Holdings are among the leading companies in the non-alcoholic steatohepatitis (NASH) market.
Non-Alcoholic Steatohepatitis (NASH) Market, by Region, 2021 (%)
Non-Alcoholic Steatohepatitis Market Size | Global Forecast 2028
Download Free Sample
Non-Alcoholic Steatohepatitis (NASH) Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product (Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib & Cenicriviroc, and Others), Application (Treatment and Diagnosis), and Sales Channel (Hospital Pharmacy, Online Provider, and Retail Pharmacy)
Non-Alcoholic Steatohepatitis Market Size | Global Forecast 2028
Download Free SampleNon-Alcoholic Steatohepatitis (NASH) Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product (Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib & Cenicriviroc, and Others), Application (Treatment and Diagnosis), and Sales Channel (Hospital Pharmacy, Online Provider, and Retail Pharmacy)
The report segments the non-alcoholic steatohepatitis (NASH) market as follows:
The non-alcoholic steatohepatitis (NASH) market is segmented on the basis of product, application, sales channel, and geography. Based on product, the market is segmented into vitamin E and pioglitazone, ocaliva, elafibranor, selonsertib & cenicriviroc, and others. Based on application, the non-alcoholic steatohepatitis (NASH) market is bifurcated into treatment and diagnosis. Based on sales channel, the non-alcoholic steatohepatitis (NASH) market is segmented into hospital pharmacy, retail pharmacy, and online provider. By geography, the non-alcoholic steatohepatitis (NASH) market is segmented as North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia Pacific), the Middle East & Africa (UAE, Saudi Arabia, South Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).
Contact Us
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com